Swedish Orphan Biovitrum
ISIN: SE0000872095 | Ticker: SOBI | LEI: 549300124Y3MQI87PT35
Country: Sweden
At Sobi, we are transforming life for people with rare diseases. As an international biopharmaceutical company, we provide access to innovative treatments in the areas of haematology, immunology and specialty care.
- Two therapeutic areas – Haematology and Immunology – and a portfolio of products within Specialty Care
- Our extended half-life factor replacement treatments are the most prescribed treatments for haemophilia - A and B respectively in several markets
- A strong portfolio of on-market products, and an extensive portfolio of pre-market assets
- An international biopharmaceutical company covering the entire value chain
- We put our focus where we can have the greatest impact, in late-stage research and development, and in patient access and commercialisation
2010
Served areaWorldwide
Headcount1,509
HeadquartersTomtebodavägen 23A, 17165 Solna – Sweden
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 48,283,000,000.00 | 48,661,000,000.00 | 52,496,000,000.00 |
| Noncurrent Assets | N/A | 40,115,000,000.00 | 39,883,000,000.00 | 41,285,000,000.00 |
| Property Plant And Equipment | N/A | 534,000,000.00 | 493,000,000.00 | 274,000,000.00 |
| Deferred Tax Assets | N/A | 611,000,000.00 | 767,000,000.00 | 877,000,000.00 |
| Current Assets | N/A | 8,168,000,000.00 | 8,778,000,000.00 | 11,210,000,000.00 |
| Inventories | N/A | 3,053,000,000.00 | 3,424,000,000.00 | 3,332,000,000.00 |
| Current Trade Receivables | N/A | 3,756,000,000.00 | 3,439,000,000.00 | 5,249,000,000.00 |
| Other Current Receivables | N/A | 465,000,000.00 | 345,000,000.00 | 558,000,000.00 |
| Cash and cash equivalents | 737,000,000.00 | 404,000,000.00 | 1,045,000,000.00 | 1,361,000,000.00 |
| Equity And Liabilities | N/A | 48,283,000,000.00 | 48,661,000,000.00 | 52,496,000,000.00 |
| Equity | N/A | 20,206,000,000.00 | 23,203,000,000.00 | 26,525,000,000.00 |
| Issued Capital | N/A | 167,000,000.00 | 169,000,000.00 | N/A |
| Issued Capital Ordinary Shares | N/A | N/A | 169,000,000.00 | 170,000,000.00 |
| Retained Earnings Profit Loss For Reporting Period | N/A | N/A | 2,679,000,000.00 | 2,638,000,000.00 |
| Retained Earnings Excluding Profit Loss For Reporting Period | N/A | N/A | 10,476,000,000.00 | 13,155,000,000.00 |
| Other Reserves | N/A | -253,000,000.00 | -66,000,000.00 | 351,000,000.00 |
| Additional Paidin Capital | N/A | 9,816,000,000.00 | 9,945,000,000.00 | 10,211,000,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 20,206,000,000.00 | 23,203,000,000.00 | 26,525,000,000.00 |
| Noncurrent Liabilities | N/A | 17,634,000,000.00 | 16,697,000,000.00 | 11,114,000,000.00 |
| Noncurrent Provisions | N/A | 252,000,000.00 | 234,000,000.00 | N/A |
| Deferred Tax Liabilities | N/A | 3,464,000,000.00 | 3,605,000,000.00 | 3,797,000,000.00 |
| Other Noncurrent Financial Liabilities | N/A | 3,473,000,000.00 | 3,834,000,000.00 | 3,899,000,000.00 |
| Longterm Borrowings | N/A | 10,137,000,000.00 | 8,777,000,000.00 | 2,971,000,000.00 |
| Current Liabilities | N/A | 10,443,000,000.00 | 8,761,000,000.00 | 14,857,000,000.00 |
| Current Provisions | N/A | N/A | 267,000,000.00 | 499,000,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 569,000,000.00 | 558,000,000.00 | 1,252,000,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | N/A | 4,700,000,000.00 | 5,253,000,000.00 |
| Current Tax Liabilities Current | N/A | 518,000,000.00 | 40,000,000.00 | 23,000,000.00 |
| Other Current Liabilities | N/A | 1,302,000,000.00 | 1,314,000,000.00 | 1,900,000,000.00 |
| Current Borrowings And Current Portion Of Noncurrent Borrowings | N/A | 4,015,000,000.00 | 1,768,000,000.00 | 5,796,000,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 15,261,000,000.00 | 15,529,000,000.00 | N/A |
| Revenue From Contracts With Customers | N/A | 15,529,000,000.00 | 18,790,000,000.00 |
| Other Income | 401,000,000.00 | 32,000,000.00 | 34,000,000.00 |
| Profit Loss From Operating Activities | 4,818,000,000.00 | 3,733,000,000.00 | 3,813,000,000.00 |
| Finance Income | 1,000,000.00 | 16,000,000.00 | 5,000,000.00 |
| Finance Costs | 602,000,000.00 | 454,000,000.00 | 497,000,000.00 |
| Profit Loss Before Tax | 4,217,000,000.00 | 3,295,000,000.00 | 3,321,000,000.00 |
| Income Tax Expense Continuing Operations | 972,000,000.00 | 616,000,000.00 | 683,000,000.00 |
| Profit (loss) | 3,245,000,000.00 | 2,679,000,000.00 | 2,638,000,000.00 |
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | 3,245,000,000.00 | 2,679,000,000.00 | 2,638,000,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -1,325,000,000.00 | -318,000,000.00 | 413,000,000.00 |
| Other Adjustments For Noncash Items | N/A | 390,000,000.00 | 529,000,000.00 | 741,000,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 333,000,000.00 | 324,000,000.00 | 309,000,000.00 |
| Interest Received Classified As Operating Activities | N/A | 1,000,000.00 | 0.00 | 5,000,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | N/A | 1,124,000,000.00 | 673,000,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 4,926,000,000.00 | 5,470,000,000.00 | 4,665,000,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 8,000,000.00 | 3,000,000.00 | 0.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 41,000,000.00 | 47,000,000.00 | 72,000,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 3,811,000,000.00 | 323,000,000.00 | 1,405,000,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -3,964,000,000.00 | -367,000,000.00 | -1,477,000,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 13,575,000,000.00 | 14,193,000,000.00 | 13,675,000,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 15,027,000,000.00 | 18,191,000,000.00 | 16,094,000,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 118,000,000.00 | 125,000,000.00 | 133,000,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -1,282,000,000.00 | -4,474,000,000.00 | -2,991,000,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -320,000,000.00 | 629,000,000.00 | 197,000,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -13,000,000.00 | 12,000,000.00 | 119,000,000.00 |
| Cash and cash equivalents | 737,000,000.00 | 404,000,000.00 | 1,045,000,000.00 | 1,361,000,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 13.02.24 | Christin Wesström | Other | Buy | SEK 3,835,982.20 |
| 09.02.24 | Christin Wesström | Other | Sell | SEK 5,654,360.50 |
| 01.12.23 | Mahmood Ladha | Other | Buy | SEK 14,993,584.00 |
| 29.11.23 | Mahmood Ladha | Other | Sell | SEK 18,529,647.36 |
| 14.11.23 | Armin Reininger | Other | Buy | SEK 13,951,500.50 |
| 10.11.23 | Armin Reininger | Other | Sell | SEK 16,141,311.01 |
| 14.09.23 | Anders Ullman | Other | Other | SEK 60,918.00 |
| 09.08.23 | Mats Lek | Other | Buy | SEK 20,309.79 |
| 09.08.23 | Linda Therese Larsson | Other | Buy | SEK 19,895.30 |
| 09.06.23 | Henrik Stenqvist | Other | Other | SEK 0.00 |
SE0000872095
LEI549300124Y3MQI87PT35
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.